BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Dihydroergotamine Methanesulfonate

A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.

9+ PubMed studies analyzed · Evidence Score: 19.7

Research Domains

Dihydroergotamine Methanesulfonate has been studied across 5 research domains including ❤️ Cardiovascular, 🧠 Focus & Attention, 😴 Sleep, 💊 Pain, 🧬 Hormones. The primary research focus is ❤️ Cardiovascular with 22% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Dihydroergotamine Methanesulfonate, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

brexpiprazole
22 shared targets
nantenine
18 shared targets
ritanserin
19 shared targets
Tamsulosin
16 shared targets
silodosin
15 shared targets
risperidone
19 shared targets
latrepirdine
16 shared targets
spiroxatrine
14 shared targets
fananserin
15 shared targets
niguldipine
18 shared targets
Loading evidence profile...

This evidence profile for Dihydroergotamine Methanesulfonate is generated deterministically from 9 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.